IDEXX Laboratories's results for Q3 2026 (quarter ended Sep 30, 2026) come from the company's own earnings release, filed with the SEC on 2026-11-02. Everything below is taken from that filing; quotes are copied exactly. Company outlooks are the company's own.
At a glance
| Item | Value |
|---|---|
| Revenue (GAAP) | $1,214 million (+9.9% vs a year earlier) |
| Diluted EPS (GAAP) | $4.01 |
| Full-year guidance | Raised |
Guidance
IDEXX raised 2026 revenue to $4,741–$4,767 million and EPS to $14.96–$15.16, while lowering operating margin to 32.1%–32.3%.
Why this label: 'Increases 2026 revenue guidance' and 'Raises 2026 EPS outlook' ($14.96-15.16); operating margin guide lowered, but margin is not a core item.
| Metric | Period | New | Prior (as stated in the release) |
|---|---|---|---|
| revenue | FY2026 | $4,741–$4,767 million (reported growth 10.1%–10.8%) | $4,700–$4,745 million (9.1%–10.3%) |
| organic revenue growth | FY2026 | 9.3%–10.0% | 8.5%–9.7% |
| EPS | FY2026 | $14.96–$15.16 | $14.69–$14.94 |
| operating margin | FY2026 | 32.1%–32.3% | 32.3%–32.5% |
| capital expenditures | FY2026 | ~$160 million | ~$180 million |
From the release
Revenue: "Revenue: · Revenue · $ · 1,214,237 · $ · 1,105,239"
Earnings per share: "Earnings per share: Diluted · $ · 4.01 · $ · 3.40"
revenue: "Revenue · $4,741 - $4,767 · $4,700 - $4,745"
organic revenue growth: "Organic growth · 9.3% - 10.0% · 8.5% - 9.7%"
EPS: "EPS · $14.96 - $15.16 · $14.69 - $14.94"
Quotes are copied from the filing; in table rows, cell borders are shown as “·”.
Key fact: Raised 2026 EPS outlook to $14.96–$15.16; Q3 revenue grew 10%.
Source
IDEXX Laboratories earnings release (SEC filing), accession 0001104659-26-120892, filed 2026-11-02.
Part of the Q3 2026 Guidance Tracker. Educational only, not advice. Free weekly recap every Sunday: yieldterminalpro.com/newsletter.